Tech Transfer eNews Blog

Epic Sciences and USC Michelson sign license agreement to advance next-generation liquid biopsy technology


By Jesse Schwartz
Published: November 24th, 2020

Epic Sciences, a company that develops novel diagnostics to help treat cancer, has entered into an exclusive license and collaboration agreement with the University of Southern California (USC)’s Michelson Center for Convergent Bioscience to enhance Epic’s platform by enabling more precise characterization of rare circulating tumor cells (CTCs).

Epic is developing CTCs into liquid-biopsy diagnostics used to characterize a patient’s cancer, allowing for more informed treatment decisions. The company’s platform provides unparalleled sensitivity and is capable of detecting one rare cell in ten million nucleated cells. It is currently being used in more than 100 clinical trials to make treatment decisions for patients with advanced prostate cancer.

Under the agreement with USC Michelson, Epic will have exclusive access to the next-generation, comprehensive liquid biopsy from the lab of researcher Peter Kuhn, whose prior work at the Scripps Research Institute formed the basis of Epic’s platform. The company aims to use the newly licensed technology to provide in-depth characterization of both the cell-free fractions and CTCs in the liquid biopsy using a number of diagnostic tools, all from a single blood draw.

“The ability to identify circulating neoplastic cells and cells from the tumor microenvironment provides additional information critical to understanding the current state of a patient’s disease and offers the ability to monitor cancer status, and response to a specific therapy,” says Rick Wenstrup, chief medical officer of Epic Sciences.

Kuhn comments, “We are excited about this collaboration with Epic Sciences intended to accelerate our goals towards improved cancer patient outcomes.”

Source: BioSpace

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment